Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for roughly $10 billion, a deal that pushes the cystic fibrosis pioneer deeper into hormone-related diseases — and, according to newly released documents, one that Vertex ultimately clinched as the sole remaining bidder.
The agreement values Crinetics at $85 per share, a 102% premium to its price before the deal, and hands Vertex a portfolio of endocrine drugs targeting conditions such as acromegaly and congenital adrenal hyperplasia. Vertex has projected the combined endocrine assets could eventually generate more than $5 billion in peak annual sales.
A one-bidder process
Regulatory filings reviewed after the announcement reveal how narrow the field became. Crinetics’ board identified six potential counterparties in late April; three declined almost immediately, one dropped out by May 1, and the final two withdrew the following week — leaving Vertex alone at the table.
Vertex first made contact on March 14 and opened with a $78-per-share proposal on March 24. The board rejected it and pushed for better terms, and over the following months Vertex stepped up its offer — $83 in mid-April, $84.50 in late May, and finally $85 on June 19, with an agreement reached July 6.
The newly released documents are “likely to reignite” investor scrutiny over whether Vertex overpaid, wrote RBC Capital Markets analyst Brian Abrahams.
Why it matters
For Vertex, the deal is a bet on diversification beyond its cystic fibrosis franchise into a new therapeutic area with durable revenue potential. For investors, the sole-bidder disclosure raises the perennial question in large acquisitions: whether a rich premium reflects strategic value or simply the absence of competing offers. Either way, it ranks among the largest biopharma acquisitions of the year.